Researchers at the National Institutes of Health have discovered that a previously unexplained fatal form of Osteogenesis Imperfecta--a disorder that weakens bones and which may cause frequent fractures--results from a genetic defect in a protein involved in the production of collagen.The study appe...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Breast cancer incidence among New Zealand women dropped by 6% from 2002 to 2003, possibly because of a decrease in hormone replacement therapy use, Madeleine Wall, clinical leader of the national screening unit's BreastScreen Aotearoa, said on Tuesday, the [click link for full article]
read more »
Source:http://www.medicalnewstoday.com DiscussBury
African-Americans with health insurance still face worse outcomes in colorectal cancer than Caucasians, Hispanics, and Asians, according to a new study. Published in the February 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that differences in ut...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Nuvo Research Inc. (TSX:NRI) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Pennsaid(R) (1.5% w/w diclofenac sodium solution), a topical non-steroidal anti-inflammatory (NSAID) developed by Nuvo for use as a treatment of osteoarthritis...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
The New York Times last week examined the debate among women, physicians and some advocates over whether breast self-exams are effective and necessary. The [click link for full article]
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival. Study results showed that the chemotherapy combination XELOX (oral Xeloda plus oxaliplatin) is as eff...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the initiation of a multi-center Phase I clinical program to explore the convenient all-oral combination of KRX-0401 (perifosine), Revlimid (lenalidomide, Celgene Corporation) and dexamethaso...
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.